Brand Name:

Biovudin^®

Dosage:

100 mg & 150 mg

Generic Name:

Lamivudine

Pharmacotherapeutic Group:

Antiviral (systemic)

Therapeutic Indication:

• Lamivudine: HIV Infection: Lamivudine in combination with other antiretroviral agents is indicated for the treatment of HIV infection.
• Chronic hepatitis B (HBV): Treatment of chronic hepatitis B associated with evidence of viral replication and active liver elimination.

Dosage and Administration:

HIV Infection:

• Adults – 300mg/day, administered as either 150mg twice daily or 300mg once daily, in combination with other antiretroviral agents.
• Children (3 months up to 16 years of age) – 4mg/kg twice daily (up to a maximum of 150mg twice a day) administered with other antiretroviral agents.

Chronic Hepatitis B:

• Adults – 100mg once daily. Safety and efficacy of treatment beyond 1year have not been established, and the optimum duration treatment is not known.
• Children (2 to 17 years of age) – 3mg/kg once daily, up to a maximum daily dose of 100mg. safety and effectiveness beyond 1year have not been established and the optimum duration of treatment is not known.

Side Effects:

• CNS: Headache; neuropathy; dizziness; sleep disturbances; depression; insomnia and other sleep disorders; depressive disorders.
• DERMATOLOGIC: Rash; alopecia; pruritus.
• GI: Nausea; vomiting; diarrhea; anorexia; abdominal pain/cramps; dyspepsia; stomatitis.
• HEMATOLOGIC: Anemia; neutropenia; hyperglycemia; weakness; lactic acidosis; lymphadenopathy; splenomegaly; lactic steatosis.
• RESPIRATORY: Nasal signs and symptoms; cough; paresthesia; abnormal breath sounds/wheezing.
• OTHER: Malaise; fatigue; fever; chills; myalgia; arthralgia; pancreatitis; elevated liver enzymes; musculoskeletal pain; anaphylaxis; urticaria; rhabdomyolysis; peripheral neuropathy; hepatic steatosis; muscle weakness with CPK elevation; posttreatment exacerbation of hepatitis.